Hypertension - Management of Acute
|
|
- Gyles Casey
- 6 years ago
- Views:
Transcription
1 Hypertensin - Management f Acute 1. Purpse Severe hypertensive disrders f pregnancy are assciated with high rates f maternal and fetal mrbidity and mrtality. It is imperative in this clinical situatin that severe bld pressure in pregnancy is treated. This guideline prvides infrmatin abut the use and administratin f ral Nifedipine, intravenus labetall and when labetall is cntraindicated, the use and administratin f intravenus hydralazine. Als refer t Prcedure: Observatins Birth Centre Adult Escalatin Criteria and Respnse Framewrk. Where prcesses differ between campuses, thse that refer t the Sandringham campus are differentiated by pink text r have the heading Sandringham campus. 2. Definitins Hydralazine is a peripheral vasdilatr that causes relaxatin f arterilar smth muscle, which results in a lwering f bld pressure. The hyptensive effect ccurs within 5-20 minutes. Maximum effect is minutes and the duratin is 2-6 hurs. The nset f the drug s actin is within 15 minutes, with a peak effect between 30 and 60 minutes. Duratin lasts between 4 and 6 hurs. Because f the slwer nset, a lading dse is required. Labetall is a nn-selective beta-adrenergic blcking agent, prducing dse-related falls in bld pressure withut reflex tachycardia and withut significant reductin in heart rate. Onset f actin f intravenus labetall is at five minutes. Peak effect ccurs at minutes. Duratin f actin is 45 minutes t six hurs. A fluid pre-lad is advisable t cunteract the ptential fr a sudden decrease in bld pressure. Nifedipine is a calcium in influx inhibitr (calcium channel blcker r calcium channel antagnist). After ral administratin, the nset f actin is 1.5 t 4.2 hurs. The half-life f an immediate release dse frm shws a mean f apprximately 1.7 t 3.4 hurs. Administratin f the tablet results in a half-life f abut 6 t 12 hurs. The pharmaclgical actin f nifedipine persists fr up t 12 hurs after administratin f the tablet. Cautin shuld be used in patients with impaired liver functin. 3. Respnsibilities Obstetric medical staff are respnsible fr the medical management f wmen with acute hypertensin. This includes prescriptin f antihypertensive medicines as apprpriate t the wman, fr advising midwifery staff f the target bld pressure and ntificatin targets, fr review f the wman and planning n-ging care. Midwifery staff are respnsible fr the midwifery care f the wman. This includes determining accurate bld pressure management and accurate fluid balance management and fr escalating care t medical staff as directed. Bth clinical grups are respnsible fr being aware f the cntraindicatins, precautins and side effects f nifedipine, labetall and hydralazine and management f same. See ver the page fr the guideline details. Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 1 f 10
2 4. Guideline Guideline Hypertensin - Management f Acute Fr all interhspital transfers W@S shuld cntact PERS (ph ). Clinical Practice Pints Hydralazine remains the drug f chice fr wmen with asthma r cngestive heart failure. Bld pressure readings must be manually recrded during the titratin phase. Bld Pressure recrding: The wman shuld be resting at an angle f greater than 45 degrees with her feet supprted. The bld pressure cuff shuld be f the apprpriate size and shuld be placed at the level f the heart. Standard cuff fr arms <33cm circumference. Large cuff (15x 33cm bladder) fr larger arms. Inflate cuff t 20-30mmHg abve palpated systlic pressure. Deflate slwly. Read and recrd bld pressure t nearest 2mmHg. Krtkff phase 5 sund (sund disappearance) is the apprpriate measurement f diastlic bld pressure. Multiple levels shuld be taken t cnfirm the diagnsis f hypertensin/ pre-eclampsia due t natural variatin. Autmated bld pressure readings may nly be cnsidered nce the maintenance dse has been achieved and the bld pressure is stable. Abrupt and prfund drps in bld pressure can ccur when vasdilatr therapy is nt accmpanied by vlume expansin in severe pre-eclampsia. This can lead t fetal bradycardia and nn-reassuring fetal status/ CTG patterns. Current literature suggests that there is n place fr blus fluid administratin prir t initiating acute antihypertensive treatment. In case f a severe hyptensive episde while infusin in prgress: cease infusin. place wman in the supine psitin, with her feet elevated and place a wedge under her right hip if undelivered (left tilt). seek urgent medical review. the infusin f plasma expanders may be required t reverse a nn-respnsive hyptensive episde. Cntinuus electrnic fetal mnitring is required fr all wmen underging IV antihypertensive management. Target bld pressure: Once the wman s BP has reached the target level then cmmence maintenance regimen aiming t maintain the systlic between and the diastlic BP at mmHg. There is rarely a need t lwer the BP further than this, and ding s may cmprmise the placental bld flw and fetus. 4.1 Nifedipine Initial management f acute hypertensin can include the use f ral immediate release nifedipine- nt slw release. Presentatin 10mg tablets. Cntraindictins Knwn hypersensitivity t nifedipine Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 2 f 10
3 Hypertensin - Management f Acute Within the first eight days after an acute episde f mycardial infarctin Cncmitant administratin with rifampicin. Precautins Nifedipine may be used in cmbinatin with beta-blcking drugs and ther antihypertensive agents, but the pssibility f ptentiatin f existing antihypertensive therapy shuld be nted Impaired hepatic functin. Adverse effects Palpitatin, peripheral edema, vasdilatatin Nausea Dizziness. Administratin Administer 10mg nifedipine rally Mnitr the bld pressure Cmmence cntinuus CTG mnitring. A secnd dse may be administered minutes later if there is inadequate respnse. Observatins f mther and fetus shuld cntinue. If there is inadequate respnse after the secnd ral dse, prceed t IV management with an alternative antihypertensive. 4.2 Labetall A stat dse f 200mg labetall can be give rally. A secnd dse may be given rally if there is n respnse within 20 minutes. If bld pressure is still nt cntrlled, IV maintenance therapy shuld be cmmenced. Intravenus labetall is cnsidered t be the primary medicine f chice fr the urgent cntrl f severe hypertensin in pregnancy. It is assciated with a lwer incidence f adverse side effects and supplants the use f hydralazine. Usage will depend n availability and the clinicians experience and familiarity with the medicine. Please nte: IV labetall is a special access scheme (SAS) drug. A frm must be cmpleted fr each patient. These can be fund in the drug rm cupbard. Presentatin Labetall hydrchlride injectin is a sterile clear slutin cntaining 5mg/mL labetall hydrchlride (Each 20mL vial cntains 100mg labetall hydrchlride). Cntraindicatins Wmen with severe hypertensin and the fllwing cnditins must nt be administered labetall (hydralazine is the alternative treatment): asthma and allergic disrders with a predispsitin t brnchspasm. cngestive heart failure. hypvlaemic shck. Refer t the prduct infrmatin fr labetall - available at pi.pdf fr a full list f cntraindicatins. Precautins The wman shuld always be nursed in and remain supine (with lateral tilt) during and up t three hurs after IV administratin due t the ptential side effects f rthstatic hyptensin. Cnsider that recent administratin f ther antihypertensive drugs, such as nifedipine may ptentiate the bld pressure lwering effect f labetall. Refer t the prduct infrmatin fr labetall - available at Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 3 f 10
4 Hypertensin - Management f Acute pi.pdf fr a full list f precautins. Cmpatibilities IMPORTANT: Refer t the Australian injectable drugs handbk (4 th editin) r cntact pharmacy fr drugs nt appearing in the table belw. Uncmmn drugs have simply been mitted and may be incmpatible. Fluids Cmpatible Sdium chlride 0.9% injectin Cmpund sdium lactate (Hartmann s) Glucse/sdium slutins Incmpatible Sdium bicarbnate 5% injectin Drugs N infrmatin Frusemide, ceftriaxne Y-Site Magnesium sulphate Adverse effects Pstural hyptensin may ccur if the initial dsage is t high r if the dse is increased t rapidly. Occasinally bradycardia and heart blck have been reprted. Transient dizziness, headache, tiredness, depressed md and lethargy may ccur. There have been reprts f a tingling sensatin f the skin (especially f the scalp) assciated with labetall treatment, usually ccurring early in treatment and is transient in nature. Refer t the prduct infrmatin fr a cmplete list f adverse effects available at: Administratin Labetall hydrchlride injectin is intended fr IV use in hspitalised patients. Labetall may be administered by IV infusin (refer t dses belw). Labetall IV blus A medical fficer must administer IV injectin dses f labetall: 20mg (4mL) administered by slw IV injectin ver tw (2) minutes. One further blus can be administered at 10 minutes if necessary. If 2 blus dses are insufficient t cntrl the bld pressure, IV therapy via infusin is required. Onset f actin f intravenus labetall is at five minutes. Peak effect ccurs at minutes. Duratin f actin is 45 minutes t six hurs.: Measure a bld pressure immediately befre, and at 5 and 10 minutes after administratin f each dse t evaluate the respnse. Cmmence an infusin f sdium chlride 0.9% r Hartmans slutin as a precautin measure t manage significant hyptensin. Cmmence cntinuus electrnic fetal mnitring. Labetall IV Infusin Wmen receiving IV infusin f labetall must be cared fr in an envirnment where ne-t-ne midwifery/nursing care can be facilitated (Birth Centre/ Cmplex Care). Prir t cmmencement the medical staff shuld explain t the wman the reasn fr administratin f the medicine, the cntinuus bservatin required and ptential adverse effects. Dsage must be individualised depending upn the severity f hypertensin and the respnse f the wman during dsing: Start the infusin at 20mg/hur. Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 4 f 10
5 Hypertensin - Management f Acute Titrate the infusin t stabilize the bld pressure by adjusting the infusin by 5mg (2.5mL f the labetall infusin with a cncentratin f 2mg/mL). Nte that the maximum dse fr 24 hurs is 300mg. Measure a bld pressure immediately befre, and at 5 and 10 minutes after administratin f each dse t evaluate the respnse. Use a labetall slutin f 2mg/mL: T make this slutin: Use a 50mL syringe: draw up 20mL (100mg f labetall slutin). Further dilute this with 30mL sdium chlride 0.9% (using 3 ampules f 10mL) t make 50mL. The resultant slutin cntains 100mg labetall (2mg/mL). This slutin gives a final cncentratin f 2mg/mL (=100mg/ 50mL) Use 2 Additive Labels t clearly identify the additive. T ensure visibility, place ne label at eye-level and the ther at the prt int the multiflw adaptr. Management f a wman receiving labetall Unless therwise cntraindicated, the wman shuld receive 300mL f Sdium Chlride 0.9% as a fluid prelad ver 15 minutes. Nte: this prelad can be safely administered t thse wmen wh are fluid restricted. Administer thrugh a syringe infusin pump. Ensure all previus histry is deleted frm that pump. See Appendix Hw t set up the Pump. Administratin and Titratin Administer dse between mg/h. The rate f infusin is t be titrated by 20mg/h (10mL/h) every 15 minutes (this equates t titrating by 5mg (2.5mL) every 15 minutes f the labetall infusin with a cncentratin f 2mg/mL) until the bld pressure is stable. See Table 1 : Labetall dse titratin via infusin pump fr guidance. Cntinue with this titratin prcess until the maximum dsage f 160 mg/hr is reached OR the wman s bld pressure is maintained at / mmHg fr tw hurs. The infusin MUST be weaned dwn. This can be achieved by reducing the dse by 20mg (2.5mL) every 15 minutes prvided the bld pressure remains stable. The maximum dse f labetall t be infused is 300mg. Table 1. Labetall dse titratin via infusin pump fr guidance Labetall dse titratin via infusin pump: cncentratin=2mg/ml Time Span Infusin rate titratin Dse t be infused ver Time in mg (ml) Pump Vlume Pump Duratin set up Ttal mg administered ver time 0 minutes 20mg/hr (10mL/hr) 5mg (2.5mL) 15 minutes 5mg 15 minutes 40 mg/hr (20mL/hr) 10mg (5 ml) 15 minutes 15mg 30 minutes 60 mg/hr (30mL/hr) 15mg (7.5 ml) 15 minutes 30mg 45 minutes 80 mg/hr (40mL/hr) 20mg (10 ml) 15 minutes 50mg 60 minutes 100mg/hr (50mL/hr) 25mg (12.5 ml) 15 minutes 75mg 75 minutes 120 mg/hr (60mL/hr) 30mg (15 ml) 15 minutes 105mg 90 minutes 140 mg/hr (70mL/hr) 35mg (17.5 ml) 15 minutes 140mg 105 minutes 160 mg/hr (80mL/hr) 40mg (20 ml) 15 minutes 180mg 120 minutes Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 5 f 10
6 Hypertensin - Management f Acute Nte: at maximum dse the wman has already received mre than half the 24 hur recmmended dse f 300mg. The time t wean ff the drug must als be cnsidered. The wman s respnse t the titratin must be reviewed at 1hur after cmmencement t determine the necessity t cntinue with this infusin r if a change in clinical management is required. Bld pressure shuld be mnitred during IV administratin. Titrate infusin and reduce bld pressure gradually t avid adverse fetal side effects frm a rapid decrease in uterplacental perfusin. Maintain cntinuus fetal mnitring f the viable fetus while endeavuring t ptimize bld pressure levels. Mnitring/bservatins Nte: Onset f actin f intravenus labetall is at five minutes. Peak effect ccurs at minutes. Duratin f actin is 45 minutes t six hurs. During titratin mnitr the bld pressure every 10 minutes, prir t each scheduled dse increase. The frequency f measurement is necessary t prevent sudden reductin in bld pressure that can affect placental perfusin. Cntinue until at least 2 stable cnsecutive readings are achieved. Once stable, bld pressure mnitring can be decreased t every half-hur. Additinal mnitring/bservatins (nce bld pressure stable): ½ hurly bld pressure, pulse, respiratry rate while infusin in prgress. 1 hurly urine utput measurement. 2 hurly temperature. 4 hurly testing f urinary prtein (full ward test). Cntinuus electrnic fetal mnitring: The viable fetus MUST be cntinuusly mnitred befre, during and after administratin f labetall. Weaning the labetall infusin: Labetall must nt be suddenly discntinued. It must be weaned ver 2 hurs. Decrease the infusin rate by 2.5mL/hr every 15 minutes. During weaning, bld pressure mnitring frequency must be increased t 15 minutely, prir t each reductin t ensure maintenance f bld pressure within target range. 4.3 Hydralazine Hydralazine is used fr the treatment f hypertensive crises - especially hypertensin assciated with pregnancy (pre-eclampsia r eclampsia). Presentatin Hydralazine ampules: 20mg dry pwder fr recnstitutin (white crystalline pwder). Cntraindicatins hypersensitivity t hydralazine. refer t full prduct infrmatin fr extensive list. Precautins cardiac dysfunctin. renal r hepatic impairment. cerebrvascular disease. refer t full prduct infrmatin fr extensive list. Cnsider that recent administratin f ther antihypertensive drugs, such as nifedipine may ptentiate the Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 6 f 10
7 Hypertensin - Management f Acute bld pressure lwering effect f labetall. Cnsider that recent administratin f ther antihypertensive drugs, such as nifedipine may ptentiate the bld pressure lwering effect f Hydralazine. Incmpatibilities Refer t the Australian injectable drugs handbk (4 th editin) fr a full list f incmpatibilities r prduct infrmatin via MIMS nline. Adverse effects The fllwing symptms are cmmn at the start f treatment with hydralazine (especially if the dse is increased rapidly): tachycardia, palpitatin, anginal symptms, flushing, headache, dizziness, nasal cngestin and gastrintestinal disturbances. Such reactins generally subside with further curse f treatment. use f hydralazine can result in sdium and fluid retentin prducing edema and reduced urinary vlume. hydralazine is knwn t crss the placenta fllwing intravenus administratin and may be assciated with fetal distress and fetal cardiac arrhythmia in the last trimester f pregnancy. Refer t full prduct infrmatin fr extensive list. Nte: Reactive tachycardia with hydralazine may necessitate the use f beta-blckers. Occasinally hypertensin resistant t hydralazine requires administratin f ther medicines (e.g., nitrprusside, glyceryl trinitrate). Wmen receiving IV infusin hydralazine must be cared fr in an envirnment where ne-t-ne midwifery/nursing care can be facilitated (Birth Centre/Cmplex Care). Prir t cmmencement the medical staff shuld explain t the wman the reasn fr administratin f the medicine, the cntinuus bservatin required and ptential adverse effects. Dse Dsage must be individualized depending n the severity f hypertensin and the respnse f the wman during dsing: Start the infusin at 1mg/min fr 10 minutes. Titrate the infusin t stabilize the bld pressure by adjusting the infusin between 1-10mg/hr t maintain a diastlic BP f mmHg. Administratin Hydralazine injectin is intended fr IV use in hspitalized patients. Hydralazine may be administered by IV infusin (refer t dses belw). Ensure an intravenus main line f sdium chlride 0.9% x 1000mL (at 80mL/hr) is insitu via a multiflw adaptr prir t the administratin f hydralazine. Recnstitutin/ set up: Requires three (3) ampules f hydralazine 20mg pwder. Recnstitute each 20mg ampule pwder with 1mL f sterile water fr injectin until disslved. Prepare 2 syringes as fllws. These can be prepared at the same time. Administer thrugh a syringe infusin pump. Ensure all previus histry is deleted frm that pump. See Appendix Hw t set up the Pump. Syringe 1: lading dse (prescribed n ONCE ONLY sectin f medicines chart: Draw up 0.5mL (10mg) cncentrate int a 10mL syringe and make up t 10mL with sdium chlride 0.9% Label the syringe and cnnect t a minimum vlume extensin set Fllw the instructins f the Alaris GH syringe driver fr Hydralazine Lading Infusin. Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 7 f 10
8 Hypertensin - Management f Acute Syringe 2: maintenance dse: Draw up 2.5mL (50mg) cncentrate int a 50mL syringe. Make up t 50mL with sdium chlride 0.9%. Label the syringe and cnnect t the Alaris GH Syringe drive fr Hydralazine Maintenance Infusin. This slutin gives a final cncentratin f 1mg/mL (= 50mg/50mL) Use 2 Additive Labels t clearly identify the additive. T ensure visibility, place ne label at eye-level and the ther at the prt int the multiflw adaptr. Dse: IV infusin Lading dse: Administer hydralazine at 1mg/min (i.e. 1mL/min f the prepared slutin) fr 10 minutes. Recrd bld pressure readings EVERY 5 MINUTES n the electrnic partgram during administratin f the intravenus lading infusin. If the bld pressure has reached the target range after 5 minutes administratin f the lading dse (i.e. 5mg), the lading dse may be ceased. Cmmence the maintenance dse. Maintenance infusin: Cntinue infusing hydralazine at 1-10mg/hr (1-10mL/hr) t maintain a diastlic BP f mmHg. Cntinue bservatin f BP every 15 minutes until stable and maintenance dse established. Maintain bservatin f BP every 30 minutes during administratin f the infusin. Mnitring/bservatins Initial mnitring/bservatins: Recrd bld pressure readings EVERY 5 MINUTES n the electrnic partgram during administratin f IV /lading dse. Cntinue bservatin f BP every 15 minutes until the BP is maintained at / mmHg fr tw hurs. The frequency f bld pressure mnitring can then be reduced t every 30 minutes fr the duratin f the infusin. The fetal heart rate is recrded every 10 minutes during the lading infusin. Other mnitring/bservatins: ½ hurly bld pressure, pulse, respiratry rate while infusin in prgress. 1 hurly urine utput measurement. 2 hurly temperature. 4 hurly testing f urinary prtein (full ward test). Cntinuus electrnic fetal mnitring: The viable fetus MUST be cntinuusly mnitred befre, during and after administratin f hydralazine. recrd n electrnic partgram and fluid balance chart. Discntinuatin f the infusin Hydralazine infusin des nt require weaning dwn and can be ceased as directed. The maximum dse f hydralazine shuld nt exceed 30 mg. Alternative antihypertensive management, such as nifedipine must be cnsidered be cnsidered if the BP is nt cntrlled nce this dse is reached. 5. Evaluatin, mnitring and reprting f cmpliance t this guideline Cmpliance t this guideline will be mnitred, evaluated and reprted by review f clinical incidents reprted Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 8 f 10
9 Hypertensin - Management f Acute n VHIMS. 6. References 1. 3Centres Cllabratin Cnsensus Guideline Hypertensin in Pregnancy, Preeclampsia and Eclampsia. March Accessed: 22 April AHFS drug infrmatin McEvy GK, ed. Hydralazine. Bethesda, MD: American Sciety f Health- System Pharmacists; 2001: Magee LA, Helewa M, Mutquin JM, vn Dadelszen P. Diagnsis, Evaluatin, and Management f the Hypertensive Disrders f Pregnancy, Jurnal f Obstetrics and Gynaeclgy Canada, JOGC, n. 206, March MIMS Online Simple Search. Accessed 22 April Natinal Health Service (NHS), Greater Glasgw and Clyde, Queen Mther s Hspital. Guidelines fr the Management f Severe Hypertensin Phebra Prduct infrmatin. Labetall Hydrchlride Injectin. 7. Ryal Cllege f Obstetricians and Gynaeclgists (RCOG), The Management f Severe Pre- Eclampsia/Eclampsia (Green-tp 10A), March Sciety f Hspital Pharmacists f Australia (AIDH). Australian Injectable Drugs Handbk. 4 th Editin Suthern Health (Mnash Medical Centre). Preeclampsia and severe preeclampsia guideline. March Ryal Wmen s Hspital plicies, guidelines and prcedures: Pre-eclampsia: Management Magnesium Sulphate Management f Hypertensive Disrders f Pregnancy Eclampsia Management 7. Legislatin related t this guideline Nt applicable. 8. Appendices 1. Hw t set up the pump Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 9 f 10
10 Hypertensin - Management f Acute PGP Disclaimer Statement The Ryal Wmen's Hspital Clinical Guidelines present statements f 'Best Practice' based n thrugh evaluatin f evidence and are intended fr health prfessinals nly. Fr practitiners utside the Wmen s this material is made available in gd faith as a resurce fr use by health prfessinals t draw n in develping their wn prtcls, guided by published medical evidence. In ding s, practitiners shuld themselves be familiar with the literature and make their wn interpretatins f it. Whilst appreciable care has been taken in the preparatin f clinical guidelines which appear n this web page, the Ryal Wmen's Hspital prvides these as a service nly and des nt warrant the accuracy f these guidelines. Any representatin implied r expressed cncerning the efficacy, apprpriateness r suitability f any treatment r prduct is expressly negated In view f the pssibility f human errr and / r advances in medical knwledge, the Ryal Wmen's Hspital cannt and des nt warrant that the infrmatin cntained in the guidelines is in every respect accurate r cmplete. Accrdingly, the Ryal Wmen's Hspital will nt be held respnsible r liable fr any errrs r missins that may be fund in any f the infrmatin at this site. Yu are encuraged t cnsult ther surces in rder t cnfirm the infrmatin cntained in any f the guidelines and, in the event that medical treatment is required, t take prfessinal, expert advice frm a legally qualified and apprpriately experienced medical practitiner. NOTE: Care shuld be taken when printing any clinical guideline frm this site. Updates t these guidelines will take place as necessary. It is therefre advised that regular visits t this site will be needed t access the mst current versin f these guidelines. Uncntrlled dcument when printed Publicatin date (16/05/2017) Page 10 f 10
Hypertension - Management of Acute
1. Purpose Severe hypertensive disorders of pregnancy are associated with high rates of maternal and fetal morbidity and mortality. It is imperative in this clinical situation that severe blood pressure
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationHyperglycaemia: Management of Preterm Infants in Neonatal Intensive Care
1. Purpse Hyperglycaemia in preterm infants is likely due t a number f factrs (impaired insulin secretin, insulin resistance and immaturity f glucse hmestasis regulatin) 1,2. Hyperglycaemia has been assciated
More informationAppendix C Guidelines for treating status epilepticus in adults and children
Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More information5.0: Rare Bleeding Disorders
5.0: Rare Bleeding Disrders 5.1: General Infrmatin Rare bleeding disrders (RBDs) include deficiencies f factrs I (Fibringen), II, V, VII, X, XI and XIII. These deficiencies can be severe r mild. Severe
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationPrinted copies of this document may not be up to date, obtain the most recent version from Author Position
Printed cpies f this dcument may nt be up t date, btain the mst recent versin frm www.cats.nhs.uk Children s Acute Transprt Service Clinical Guidelines Diabetic Ketacidsis Dcument Cntrl Infrmatin Authr
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationHYPERTENSION AN OVERVIEW. Compiled by. Campbell M Gold (2008) CMG Archives --()-- IMPORTANT
HYPERTENSION AN OVERVIEW Cmpiled by Campbell M Gld (2008) CMG Archives http://campbellmgld.cm IMPORTANT The health infrmatin cntained herein is nt meant as a substitute fr advice frm yur physician, r ther
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.5 Cmpleted: June 14, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationPackage leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate
Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationPaediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead
Paediatric Sepsis Frm Sinéad Hrgan SSWHG Sepsis Lead www.hse.ie/sepsis Definitin A life-threatening rgan dysfunctin due t a dysregulated hst respnse t infectin N cnfirmatry test Bld cultures are psitive
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationEAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL
EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL Cncussin awareness has increased significantly in recent years. The Natinal Cllegiate Athletic Assciatin (NCAA), Natinal Athletic Trainers Assciatin
More informationUrinary Retention: Inability to pass urine despite the presence of urine in the bladder.
FOCUS The assessment and treatment f acute urinary retentin thrugh perfrmance f straight intermittent catheterizatin. This guideline des nt refer t the nging management f urinary retentin. BACKGROUND Ratinale
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationMagnesium Sulphate - Management of Hypertensive Disorders of Pregnancy
1. Purpose Magnesium sulphate is the anticonvulsant of choice for pre-eclampsia prophylaxis and treatment. This clinical guideline outlines the indications, contraindications, administration and monitoring
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationProtocol. Preparation Protocol for the Non-Targeted Vevo MicroMarker Contrast Agent
Prtcl Preparatin Prtcl fr the Nn-Targeted Vev MicrMarker Cntrast Agent System Cmpatibility: This guide cntains instructins and suggestins fr wrk n the Vev2100, VevLAZR, Vev 3100 systems and transducers
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationCoding. Training Guide
Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationHow to become an AME Online
Hw t becme an AME Online 1. Check that yu meet the minimum technical requirements in rder t use the AME Online system: Operating System: Windws Vista (Service Pack 2) Windws 7 Windws 8, 8.1 Windws 10 Please
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationSCALES NW HEARING PROTECTION PROGRAM
PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationBedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:
Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationRoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation
RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationEMC believes the information in this publication is accurate as of its publication date. The information is subject to change without notice.
EMC DATA PROTECTION ADVISOR (DPA) MIGRATION TECH NOTE With SQL as external database fr t 5.5.1 and later DPA versin 5.x releases t 6.0 SP1 and later ABSTRACT This Tech Nte prvides the steps t migrate frm
More informationPART III: CONSUMER INFORMATION
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationBenepali (etanercept): Brief training on additional Risk Minimisation Measures
Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is
More informationHPV VACCINATION IN SANDYFORD SERVICES
HPV VACCINATION IN SANDYFORD SERVICES 1. General infrmatin n HPV Vaccinatin 2. HPV vaccinatin in females 3. Yung Wmen Only 4. HPV vaccinatin in MSM 1. General infrmatin General Infrmatin fr clinicians
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationMeasure Specific Guidelines for Comprehensive Diabetes Care (CDC)
Measure Specific Guidelines fr Cmprehensive Diabetes Care (CDC) Descriptin: Members age 18-75 years f age with diabetes (Type 1 and Type 2)* that had all f the fllwing: *Members in hspice are excluded
More informationMedication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection
Medicatin Guide SIGNIFOR [sig-na-fr] (pasiretide) Injectin Read this Medicatin Guide befre yu start using SIGNIFOR and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)
1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationUniversity College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service
University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationMEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP
MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationPROTOCOL 1850 Millrace Drive, Suite 3A Eugene, Oregon
PROTOCOL Cmplex II Enzyme Activity Micrplate Assay Kit 1850 Millrace Drive, Suite 3A Eugene, Oregn 97403 MS241 Rev.0 DESCRIPTION Cmplex II Enzyme Activity Micrplate Assay Kit Sufficient materials are prvided
More informationTrust Protocol for the prevention and treatment of Fat Malabsorption in Adults with Cystic Fibrosis.
Trust Prtcl fr the preventin and treatment f Fat Malabsrptin in Adults with Cystic Fibrsis. A Clinical Plicy Nrflk and Nrwich University Hspital Fr Use in: Fundatin Trust Cystic Fibrsis (CF) team including
More informationManaging the Symptoms of Stroke
Unit 26: Recgnising and Managing the Symptms f Strke Unit reference number: F/616/7312 Level: 2 Unit type: Optinal Credit value: 3 Guided learning hurs: 28 Unit summary A strke can be a life-threatening
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationWaterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION
Waterl Wellingtn Rehabilitative Care System Integrated Care Pathway fr STROKE Stream f Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION Care Setting Activity Patients wh present t a cmmunity
More informationLow Molecular Weight Heparin Prescribing and Administration (Adults)
Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationQP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #:
QP Energy Services LLC Hearing Cnservatin Prgram HSE Manual Sectin 7 Effective Date: 5/30/15 Revisin #: Prepared by: James Aregd Date: 5/30/15 Apprved by: James Aregd Date: 5/30/15 Page 1 f 8 Cntents Sectin
More informationPercutaneous Nephrolithotomy (PCNL)
Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this
More informationMEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP
MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationPackage leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationRituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY
Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Backgrund and indicatins Rituximab is a mnclnal antibdy that wrks by remving B-cells (a type f white bld cell that prduce antibdies). The aim f the B cell
More informationThank you for committing to engage pharmacists regarding the incredible opportunity for them to prevent opioid overdose deaths by providing naloxone!
Thank yu fr cmmitting t engage pharmacists regarding the incredible pprtunity fr them t prevent piid verdse deaths by prviding nalxne! If yu encunter cmplicated questins that yu are unable t answer, please
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More information(Please text me on once you have submitted your request online and the cell number you used)
Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More information